The Future of ANCA-associated Vasculitis

Julia U. Holle; Stefan Wieczorek; Wolfgang L. Gross

doi:10.1016/j.rdc.2010.05.007

The Future of ANCA-associated Vasculitis

Julia U. Holle^*, Stefan Wieczorek, Wolfgang L. Gross

^*Corresponding author for this work

Department of Rheumatology and Clinical Immunology

Ruhr-University Bochum

6 Citations (Scopus)

Abstract

The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient outcomes. There is a need for diagnostic criteria; treatment strategies need further improvement to reduce the toxicity of conventional immunosuppressants such as cyclophosphamide. The elucidation of the genetic background in patients with AAV and the role of granulomatous lesions found in Wegener's granulomatosis are required to fully understand the pathophysiology of AAV.

Original language	English
Journal	Rheumatic Disease Clinics of North America
Volume	36
Issue number	3
Pages (from-to)	609-621
Number of pages	13
ISSN	0889-857X
DOIs	https://doi.org/10.1016/j.rdc.2010.05.007
Publication status	Published - 08.2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1016/j.rdc.2010.05.007

Cite this

@article{aea0406cb1be4991bd900502c7d00a83,

title = "The Future of ANCA-associated Vasculitis",

abstract = "The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient outcomes. There is a need for diagnostic criteria; treatment strategies need further improvement to reduce the toxicity of conventional immunosuppressants such as cyclophosphamide. The elucidation of the genetic background in patients with AAV and the role of granulomatous lesions found in Wegener's granulomatosis are required to fully understand the pathophysiology of AAV.",

author = "Holle, \{Julia U.\} and Stefan Wieczorek and Gross, \{Wolfgang L.\}",

year = "2010",

month = aug,

doi = "10.1016/j.rdc.2010.05.007",

language = "English",

volume = "36",

pages = "609--621",

journal = "Rheumatic Disease Clinics of North America",

issn = "0889-857X",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - The Future of ANCA-associated Vasculitis

AU - Holle, Julia U.

AU - Wieczorek, Stefan

AU - Gross, Wolfgang L.

PY - 2010/8

Y1 - 2010/8

N2 - The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient outcomes. There is a need for diagnostic criteria; treatment strategies need further improvement to reduce the toxicity of conventional immunosuppressants such as cyclophosphamide. The elucidation of the genetic background in patients with AAV and the role of granulomatous lesions found in Wegener's granulomatosis are required to fully understand the pathophysiology of AAV.

AB - The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient outcomes. There is a need for diagnostic criteria; treatment strategies need further improvement to reduce the toxicity of conventional immunosuppressants such as cyclophosphamide. The elucidation of the genetic background in patients with AAV and the role of granulomatous lesions found in Wegener's granulomatosis are required to fully understand the pathophysiology of AAV.

UR - https://www.scopus.com/pages/publications/77955242704

U2 - 10.1016/j.rdc.2010.05.007

DO - 10.1016/j.rdc.2010.05.007

M3 - Scientific review articles

C2 - 20688253

AN - SCOPUS:77955242704

SN - 0889-857X

VL - 36

SP - 609

EP - 621

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

IS - 3

ER -

The Future of ANCA-associated Vasculitis

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this